Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 24;10(1):6.
doi: 10.1186/s40708-022-00183-3.

Harnessing the potential of machine learning and artificial intelligence for dementia research

Affiliations
Review

Harnessing the potential of machine learning and artificial intelligence for dementia research

Janice M Ranson et al. Brain Inform. .

Abstract

Progress in dementia research has been limited, with substantial gaps in our knowledge of targets for prevention, mechanisms for disease progression, and disease-modifying treatments. The growing availability of multimodal data sets opens possibilities for the application of machine learning and artificial intelligence (AI) to help answer key questions in the field. We provide an overview of the state of the science, highlighting current challenges and opportunities for utilisation of AI approaches to move the field forward in the areas of genetics, experimental medicine, drug discovery and trials optimisation, imaging, and prevention. Machine learning methods can enhance results of genetic studies, help determine biological effects and facilitate the identification of drug targets based on genetic and transcriptomic information. The use of unsupervised learning for understanding disease mechanisms for drug discovery is promising, while analysis of multimodal data sets to characterise and quantify disease severity and subtype are also beginning to contribute to optimisation of clinical trial recruitment. Data-driven experimental medicine is needed to analyse data across modalities and develop novel algorithms to translate insights from animal models to human disease biology. AI methods in neuroimaging outperform traditional approaches for diagnostic classification, and although challenges around validation and translation remain, there is optimism for their meaningful integration to clinical practice in the near future. AI-based models can also clarify our understanding of the causality and commonality of dementia risk factors, informing and improving risk prediction models along with the development of preventative interventions. The complexity and heterogeneity of dementia requires an alternative approach beyond traditional design and analytical approaches. Although not yet widely used in dementia research, machine learning and AI have the potential to unlock current challenges and advance precision dementia medicine.

Keywords: Animal models; Artificial intelligence; Dementia; Drug discovery; Genetics; Machine learning; Neuroimaging; Prevention; iPSC.

PubMed Disclaimer

Conflict of interest statement

AK declares research grant funding from GlaxoSmithKline. All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Growth in citations related to AI in dementia research. Source: PubMed citations using the search term (Alzheimer*[Title/Abstract] OR dement*[Title/Abstract]) AND (AI[Title/Abstract] OR artificial intelligence[Title/Abstract] OR machine learning[Title/Abstract])

Similar articles

  • Artificial intelligence for dementia prevention.
    Newby D, Orgeta V, Marshall CR, Lourida I, Albertyn CP, Tamburin S, Raymont V, Veldsman M, Koychev I, Bauermeister S, Weisman D, Foote IF, Bucholc M, Leist AK, Tang EYH, Tai XY; Deep Dementia Phenotyping (DEMON) Network; Llewellyn DJ, Ranson JM. Newby D, et al. Alzheimers Dement. 2023 Dec;19(12):5952-5969. doi: 10.1002/alz.13463. Epub 2023 Oct 14. Alzheimers Dement. 2023. PMID: 37837420 Free PMC article. Review.
  • Artificial intelligence for neurodegenerative experimental models.
    Marzi SJ, Schilder BM, Nott A, Frigerio CS, Willaime-Morawek S, Bucholc M, Hanger DP, James C, Lewis PA, Lourida I, Noble W, Rodriguez-Algarra F, Sharif JA, Tsalenchuk M, Winchester LM, Yaman Ü, Yao Z; Deep Dementia Phenotyping (DEMON) Network; Ranson JM, Llewellyn DJ. Marzi SJ, et al. Alzheimers Dement. 2023 Dec;19(12):5970-5987. doi: 10.1002/alz.13479. Epub 2023 Sep 28. Alzheimers Dement. 2023. PMID: 37768001 Review.
  • Artificial intelligence to revolutionize IBD clinical trials: a comprehensive review.
    Sedano R, Solitano V, Vuyyuru SK, Yuan Y, Hanžel J, Ma C, Nardone OM, Jairath V. Sedano R, et al. Therap Adv Gastroenterol. 2025 Feb 23;18:17562848251321915. doi: 10.1177/17562848251321915. eCollection 2025. Therap Adv Gastroenterol. 2025. PMID: 39996136 Free PMC article. Review.
  • Artificial intelligence for dementia drug discovery and trials optimization.
    Doherty T, Yao Z, Khleifat AAL, Tantiangco H, Tamburin S, Albertyn C, Thakur L, Llewellyn DJ, Oxtoby NP, Lourida I; Deep Dementia Phenotyping (DEMON) Network; Ranson JM, Duce JA. Doherty T, et al. Alzheimers Dement. 2023 Dec;19(12):5922-5933. doi: 10.1002/alz.13428. Epub 2023 Aug 16. Alzheimers Dement. 2023. PMID: 37587767 Review.
  • Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia.
    Winchester LM, Harshfield EL, Shi L, Badhwar A, Khleifat AA, Clarke N, Dehsarvi A, Lengyel I, Lourida I, Madan CR, Marzi SJ, Proitsi P, Rajkumar AP, Rittman T, Silajdžić E, Tamburin S, Ranson JM, Llewellyn DJ. Winchester LM, et al. Alzheimers Dement. 2023 Dec;19(12):5860-5871. doi: 10.1002/alz.13390. Epub 2023 Aug 31. Alzheimers Dement. 2023. PMID: 37654029 Free PMC article. Review.

Cited by

References

    1. Alzheimer’s Association. What Is Dementia? https://www.alz.org/alzheimers-dementia/what-is-dementia. Accessed 16 Feb 2019.
    1. Wightman DP, Jansen IE, Savage JE, et al. Largest GWAS (N=1,126,563) of Alzheimer’s Disease Implicates Microglia and Immune Cells. medRxiv 2020:2020.2011.2020.20235275.
    1. Finucane HK, Bulik-Sullivan B, Gusev A, et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat Genet. 2015;47:1228–1235. doi: 10.1038/ng.3404. - DOI - PMC - PubMed
    1. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. PLoS Comput Biol. 2015;11:e1004219. doi: 10.1371/journal.pcbi.1004219. - DOI - PMC - PubMed
    1. Escott-Price V, Hardy J. Genome-wide association studies for Alzheimer’s disease: bigger is not always better. Brain Commun. 2022;4:8. doi: 10.1093/braincomms/fcac125. - DOI - PMC - PubMed

LinkOut - more resources